No Detail Found!

Monocyte-to-Hdl-Cholesterol Ratio as a Prognostic Marker in Covid-19

Author(s)
Hasan Ergenc Department of Internal Medicine, Ayancık State Hospital,Sinop,Turkey
Zeynep Ergenc Department of Internal Medicine, Ayancık State Hospital,Sinop,Turkey
Hasan Tahsin Gozdas Department of Infectious Diseases and Clinical Microbiology, Abant Izzet Baysal University, Faculty of Medicine,Bolu,Turkey
Ozlem Karaca Ocak Department of General Surgeon, Medicana International Hospital,Samsun,Turkey
Ozgur I˙nce Department of Pulmonology, Medicana International Hospital,Samsun,Turkey
Tayibe Bal Department of Infectious Diseases and Clinical Microbiology, Mustafa Kemal University, Faculty of Medicine,Hatay,Turkey
Abstract
Background: There is an urgent need for mortality predictors for COVID-19 so that clinicians can diagnose severe cases and triage them as soon as possible. Many studies have suggested using hematologic markers to predict mortality and severity of COVID-19 disease. This study investigates the use of monocyte-to-high density lipoprotein cholesterol ratio (MHR) as a predictive marker for COVID-19 severity and mortality. Methods: This retrospective cross-sectional study was performed on 81 PCR-confirmed COVID-19 patients between 25 March 2020 to 26 June 2020. Patients were classified into two presentation categories: the non-severe group (n=37) and the severe group (n=44). Patients in the severe group were also divided into two subgroups: severe survivors (n=14) and severe non-survivors (n=30). In the receiver operating characteristic (ROC) analysis, optimal cut-off values of the monocyte count, high-density lipoprotein cholesterol (HDL-C), and MHR were calculated for the differentiation of severe and non-severe COVID-19 patients, as well as survivors and non-survivors. Results: A total of 81 patients, 29 (35.8%) males and 52 (64.2) females, with a median age of 71 (IQR 63-81) years. Both HDL-C and MHR showed a reasonable ability to distinguish severe disease from non-severe disease, while MHR had a higher area under curve (AUC) than HDL-C (0.799, 95%CI 0.704-0.894, p<0.001 vs 0.734, 95% Cl 0.626-0.843, p<0.001). Only MHR could distinguish survivors from non-survivors with an ROC AUC of 0.735 (95%Cl 0.619-0.850). The optimal cut-off values of MHR for predicting severe disease were 0.0061 (sensitivity: 66% and specificity: 66%) and 0.0066 (sensitivity: 70% and specificity: 62%) for predicting mortality. The optimal cut-off value of MHR for predicting severe disease was 0.0061 (sensitivity: 66% and specificity: 66%), and it was 0.0066 for predicting mortality among patients with severe disease (sensitivity: 70% and specificity: 62%). Conclusion: Our results showed that MHR was observed to be able to distinguish severe COVID-19 patients from non-severe patients as well as survivors from non-survivors.
Publication Details
Page(s) 116-122
Published Journal: Journal of Pioneering Medical Sciences, Volume: 13, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
COVID-19, Mortality, Severity, Covid-19, Monocyte-to-HDL-cholesterol ratio
References
Artifoni M.,Danic G.,Gautier G.,Gicquel P.,Boutoille D.,Raffi F.,Lecomte R. .2020 .Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. Journal of Thrombosis and Thrombolysis, 50 : 211-216.
de Meira Leite M.,Gonzalez-Galarza F. F.,da Silva B. C. C.,Middleton D.,Dos Santos E. J. M. .2021 .Predictive immunogenetic markers in COVID-19. , 82(4) : 247-254.
Marin Gallo,Aghagoli B.,Lavine G.,Yang K.,Siff L.,Chiang E. J.,Michelow S. S.,I. C. S. S. .2021 .Predictors of COVID-19 severity: a literature review. Reviews in Medical Virology, 31(1) : 1-10.
Ma H.,Li Q.,Liu C.,Zhao R.,Wang L.,Xia W.,Y. W. .2020 .Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerging Microbes & Infections, 9(1) : 1123-1130.
Hasty F.,García G.,Dávila H.,Wittels S. H.,Hendricks S.,Chong S. .2021 .Heart rate variability as a possible predictive marker for acute inflammatory response in COVID-19 patients. Military Medicine, 186(1- 2) : e34-e38.
Qin J. J,Zhou F.,Lei F.,Akolkar G.,Cai J.,Li H. .2020 .Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19. , 76(4) : 1104-1112.
Sugiyama M.,Kinoshita N.,Ide S.,Nomoto H.,Nakamoto T.,Saito S.,Mizokami M. .2021 .Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. , 766 : 145145.
Yan L.,Zhang L.,Goncalves J.,Xiao Y.,Wang M.,Guo Y.,Yuan Y. .2020 .An interpretable mortality prediction model for COVID19 patients. Nature Machine Intelligence, 2(5) : 283-288.
Asghar M. S.,Kazmi S. J. H.,Khan N. A.,Akram M.,Hassan M.,Rasheed U.,Khan S. A. .2020 .Poor prognostic biochemical markers predicting fatalities caused by COVID-19: a retrospective observational study from a developing country. Cureus, 12(8) : .
Del Valle D. M.,Kim-Schulze S.,Huang H. H.,Beckmann N. D.,Nirenberg S.,Wang B.,Gnjatic S. .2020 .An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 26(10) : 1636-1643.
Goshua G.,Pine A. B.,Meizlish M. L.,Chang C. H.,Bahel P.,Lee A. I. .2020 .Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology, 7(8) : e575-e582.
Harmouch F.,Shah K.,Hippen J. T.,Kumar A.,Goel H. .2021 .Is it all in the heart? Myocardial injury as major predictor of mortality among hospitalized COVID-19 patients. Journal of Medical Virology, 93(2) : 973-982.
Kuluöztürk M.,In M.,Telo S.,Karabulut E.,Geçkil A. A. .2021 .Efficacy of copeptin in distinguishing COVID-19 pneumonia from community-acquired pneumonia. Journal of Medical Virology, 93(5) : 3113-3121.
Philippe A.,Chocron R.,Gendron N.,Bory O.,Beauvais A.,Peron N.,Smadja D. M. .2021 .Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis, 1 : 13.
Shang W.,Dong J.,Ren Y.,Tian M.,Li W.,Hu J.,Li Y. .2020 .The value of clinical parameters in predicting the severity of COVID-19. Journal of Medical Virology, 92(10) : 2188-2192.
Çakır I.,Günay N. E.,Pangal D.,Sert G. A.,Duru N. .2020 .Monocyte to High-Density Lipoprotein Ratio: A Novel Inflammation Marker Related to Diabetic Retinopathy. Erciyes Medical Journal/Erciyes Tip Dergisi, 42(2) : 190-5.
Davidson W. S.,Shah A. S. .2019 .High-density lipoprotein subspecies in health and human disease: focus on type 2 diabetes. Methodist DeBakey Cardiovascular Journal, 15(1) : 55-61.
Haghikia A.,Landmesser U. .2018 .High-density lipoproteins: effects on vascular function and role in the immune response. Cardiology Clinics, 36(2) : 317-327.
Karatas A.,Turkmen E.,Erdem E.,Dugeroglu H.,Kaya Y. .2018 .Monocyte to high-density lipoprotein cholesterol ratio in patients with diabetes mellitus and diabetic nephropathy. Biomarkers in Medicine, 12(9) : 953-959.
Rye K. A. .2013 .High density lipoprotein structure, function, and metabolism: a new Thematic Series. Journal of Lipid Research, 54(8) : 2031-2033.
Rizzo P.,Fortini F.,Marracino F.,Rapezzi L.,Ferrari C.,R. C. .2020 .COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm?. , 115 : 1-8.
Zheng Y. Y.,Ma Y. T.,Zhang J. Y.,Xie X. .2020 .COVID-19 and the cardiovascular system. Nature reviews cardiology, 17(5) : 259-260.
Tan W.,Aboulhosn J. .2020 .The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. International journal of Cardiology, 309 : 70-77.
Wang D.,Hu B.,Hu C.,Zhu F.,Liu X.,Zhang X.,Peng Z. .2020 .Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. , 323(11) : 1061-1069.
Li Z.,Yang T.,Han D.,Mi X.,Li Y.,Guo X. .2020 .Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain. Frontiers of Medicine, 14 : 533-541.
Sun J.,Aghemo A.,Forner A.,Valenti L. .2020 .COVID-19 and liver disease. Liver International, 40(6) : 1278-1281.
Zhang C.,Shi L.,Wang F. S. .2020 .Liver injury in COVID-19: management and challenges. The Lancet Gastroenterology & Hepatology, 5(5) : 428-430.
Luo Y.,Wang R.,Zhang K.,Wang M.,Dong Z.,Xu L.,G. L. .2020 .Kidney disease is associated with in-hospital death of patients with COVID-19. , 97(5) : 829-838.
Naicker S.,Yang C. W.,Hwang S. J.,Liu B. C.,Chen J. H.,Jha V. .2020 .The novel coronavirus 2019 epidemic and kidneys. , 97(5) : 824-828.
Chen N.,Zhou M.,Dong X.,Qu J.,Gong J.,Han Y.,Zhang L. .2020 .Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395(10223) : 507-513.
Wu T. T.,Zheng Y. Y.,Chen Y.,Yu Z. X.,Ma Y. T.,Xie X. .2019 .Monocyte to high-density lipoprotein cholesterol ratio as longterm prognostic marker in patients with coronary artery disease undergoing percutaneous coronary intervention. Lipids in Health and Disease, 18 : 1-10.
Demirbas ¸,Elmas A.,Atasoy Ö. F.,Türsen M.,Lotti T. .2021 .Can monocyte to HDL cholesterol ratio and monocyte to lymphocyte ratio be markers for inflammation and oxidative stress in patients with vitiligo? A preliminary study. Archives of Dermatological Research, 313 : 491-498.
Canpolat U.,Çetin E. H.,Cetin S.,Aydin S.,Akboga M. K.,Yayla C.,Aydogdu S. .2016 .Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clinical and Applied Thrombosis/Hemostasis, 22(5) : 476-482.
Mirza Z.,Oltulu E.,Katipoglu R.,B. R. .2020 .May monocyte/HDL cholesterol ratio (MHR) and neutrophil/lymphocyte ratio (NLR) be an indicator of inflammation and oxidative stress in patients with keratoconus?. Ocular Immunology and Inflammation, 28(4) : 632-636.
Devaraj S.,Vega G.,Lange R.,Grundy S. M.,Jialal I. .1998 .Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. The American Journal of Medicine, 104(5) : 445-450.
Kucur M.,Isman F. K.,Karadag B.,Vural V. A.,Tavsanoglu S. .2007 .Serum YKL-40 levels in patients with coronary artery disease. Coronary Artery Disease, 18(5) : 391-396.
Lichtman J. H.,Amatruda J.,Yaari J.,Smith G. L.,Mattera J. A.,Krumholz H. M. .2004 .Clinical trial of an educational intervention to achieve recommended cholesterol levels in patients with coronary artery disease. American Heart Journal, 147(3) : 522-528.
Sachdeva A.,Cannon C. P.,Deedwania P. C.,LaBresh K. A.,Smith Jr S. C.,Dai D.,Fonarow G. C. .2009 .Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. American Heart Journal, 157(1) : 111-117.
Hu X.,Chen D.,Wu L.,He G.,Ye W. .2020 .Low serum cholesterol level among patients with COVID-19 infection in Wenzhou, China. China (February, 21 : .
0

Citations

0

Downloads

30

Views